News

Published on 26 Apr 2022 on Zacks via Yahoo Finance

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?


Article preview image

We expect investors to focus on the sales performance of Assertio Holdings’ ASRT marketed drugs when it reports first-quarter 2022 results on May 9, after the market closes.

ASRT’s earnings surpassed expectations in two of the trailing four quarters and missed the same on the other two occasions, the average surprise being 20.8%. In the last reported quarter, Assertio Holdings witnessed a negative earnings surprise of 16.7%.

Assertio Holdings, Inc. Price and EPS Surprise

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues

Halozyme Therapeutics, Inc. HALO reported first-quarter 2022 adjusted earnings of 47 cents per sh...

Zacks via Yahoo Finance 11 May 2022

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

We expect investors to focus on the sales performance of Assertio Holdings’ ASRT marketed drugs w...

Zacks via Yahoo Finance 26 Apr 2022

Sarcoidosis Therapeutics Market to record USD 64.82 Mn growth | North American market to create...

NEW YORK, April 26, 2022 /PRNewswire/ -- The "Sarcoidosis Therapeutics Market" report by Technavi...

WFMZ Eastern Pennsylvania and Western New Jersey 26 Apr 2022

Deal Watch: Skadden, Wilson Sonsini, Simpson and Davis Polk Usher in Musk Era at Twitter | The...

Elon Musk, leaning on Skadden, Arps, Slate, Meagher & Flom for legal advice, struck a deal on Mon...

Law.com 26 Apr 2022

Analysts Are Downgrading These 10 Pharmaceutical Stocks

In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. Y...

Insider Monkey via Yahoo Finance 20 Apr 2022

Looking Into Antares Pharma Inc's Recent Short Interest

Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. T...

Benzinga 14 Apr 2022

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

Halozyme Therapeutics HALO announced that it has entered into a definitive agreement with Antares...

Zacks via Yahoo Finance 14 Apr 2022

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

Antares Pharma ATRS shares ended the last trading session 49.2% higher at $5.58. The jump came on...

Zacks via Yahoo Finance 14 Apr 2022

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60...

Benzinga via Yahoo Finance 13 Apr 2022

Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium

Shares of Antares Pharma Inc. rocketed 46.3% in premarket trading Wednesday toward a two-decade h...

MarketWatch 13 Apr 2022